Trial Profile
A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 23 Nov 2022
Price :
$35
*
At a glance
- Drugs Epacadostat (Primary) ; Pembrolizumab (Primary) ; Carboplatin; Cyclophosphamide; Fluorouracil; Folinic acid; Gemcitabine; Oxaliplatin; Paclitaxel; Pemetrexed
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Acronyms ECHO-207-KEYNOTE-723
- Sponsors Incyte Corporation
- 03 Nov 2022 Results published in the Oncologist
- 02 Dec 2020 Status changed from active, no longer recruiting to completed.
- 27 Apr 2020 Planned End Date changed from 1 Jan 2020 to 1 Nov 2020.